LC3-associated phagocytosis (LAP): a potentially influential mediator of efferocytosis-related tumour progression and aggressiveness.

Files

hdl_145327.pdf (2.72 MB)
  (Published version)

Date

2020

Authors

Asari, P.
Roscioli, E.
Hurtado, P.
Tran, H.
Mah, C.
Hodge, S.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Frontiers in Oncology, 2020; 10:1298-1-1298-14

Statement of Responsibility

Patrick F. Asare, Eugene Roscioli, Plinio R. Hurtado, Hai B. Tran, Chui Yan Mah, and Sandra Hodge

Conference Name

Abstract

One aim of cancer therapies is to induce apoptosis of tumor cells. Efficient removal of the apoptotic cells requires coordinated efforts between the processes of efferocytosis and LC3-associated phagocytosis (LAP). However, this activity has also been shown to produce anti-inflammatory and immunosuppressive signals that can be utilized by live tumor cells to evade immune defense mechanisms, resulting in tumor progression and aggressiveness. In the absence of LAP, mice exhibit suppressed tumor growth during efferocytosis, while LAP-sufficient mice show enhanced tumor progression. Little is known about how LAP or its regulators directly affect efferocytosis, tumor growth and treatment responses, and identifying themechanisms involved has the potential to lead to the discovery of novel approaches to target cancer cells. Also incompletely understood is the direct effect of apoptotic cancer cells on LAP. This is particularly important as induction of apoptosis by current cytotoxic cancer therapies can potentially stimulate LAP following efferocytosis. Herein, we highlight the current understanding of the role of LAP and its relationship with efferocytosis in the tumor microenvironment with a view to presenting novel therapeutic strategies.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2020 Asare, Roscioli, Hurtado, Tran, Mah and Hodge. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

License

Grant ID

Call number

Persistent link to this record